title: [Treatment of patients with invasive bladder cancer].
abstract: Radical surgery was made in 85 patients with invasive cancer of the bladder. 89.4% patients had the tumor of stage T2-T3. After the operation all 85 patients received 3 courses of adjuvant chemotherapy M-VAC in modification of the Cancer Research Center. The interval between the courses was 3 weeks. The patients were divided into two groups. The test group (n = 43) received surgical treatment, M-VAC chemotherapy and immunocorrection (general magnetotherapy, phytotherapy = cyclopheron). The control group (n = 42) received only surgery and adjuvant chemotherapy. It was found that the above immunocorrection reduces the number of postoperative complications 3.8 times, side effects by chemotherapy by 1.4 times. Absolute count of T lymphocytes and their active forms elevated by 42.8 and 35.7%, respectively, while CIC diminished by 48.8%. The addition of immunocorrection to combined treatment of patients with invasive cancer of the bladder decreased the number of recurrences for 2 years twice. 3-year survival was 1.5 times longer.
authors.forename: S A
authors.initials: SA
authors.lastname: Varlamov
authors.forename: A F
authors.initials: AF
authors.lastname: Lazarev
authors.forename: A I
authors.initials: AI
authors.lastname: Neĭmark
authors.forename: V Iu
authors.initials: VIu
authors.lastname: Tat'ianin
authors.forename: D I
authors.initials: DI
authors.lastname: Ganov
authors.forename: N Iu
authors.initials: NIu
authors.lastname: P'iankova
mesh_terms: D000166:Acridines / Q000627:therapeutic use; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D015653:Cystectomy; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D018655:Lymphocyte Count; D008280:Magnetics / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local; D008517:Phytotherapy; D011183:Postoperative Complications / Q000517:prevention & control; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D000166:Acridines; D000276:Adjuvants, Immunologic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; C026430:10-carboxymethyl-9-acridanone; D008727:Methotrexate